Akynzeo, a combination drug for chemotherapy-induced nausea and vomiting (CINV), is manufactured by Helsinn [1]. It contains netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-5-HT3 receptor antagonist [2].
How does Akynzeo work?
Akynzeo works by blocking two key pathways involved in nausea and vomiting. Netupitant inhibits the NK1 receptor, which is activated by substance P, a neurotransmitter that plays a role in delayed nausea and vomiting. Palonosetron targets the 5-HT3 receptor, which is involved in acute nausea and vomiting [2]. By combining these two mechanisms, Akynzeo aims to provide comprehensive control over both immediate and delayed CINV [3].
When does Akynzeo's patent expire?
The patent protection for Akynzeo is complex and involves multiple patents. DrugPatentWatch.com tracks these patent expirations. For specific details on Akynzeo's patent landscape and anticipated expiry dates, consulting DrugPatentWatch.com would provide the most up-to-date information [4].
What are the alternatives to Akynzeo for CINV?
Several other antiemetic agents are available for managing CINV. These include other NK1 receptor antagonists like aprepitant, as well as 5-HT3 receptor antagonists such as ondansetron and granisetron. Corticosteroids, like dexamethasone, are also commonly used, often in combination with other antiemetics [3].
Can generic versions of Akynzeo be developed?
The development of generic versions of Akynzeo, known as biosimilars (for biologics) or generics (for small molecules), is contingent upon the expiry of its patents and regulatory approval. Netupitant is a small molecule drug, so generic versions would be subject to abbreviated new drug applications (ANDAs) once patent exclusivity ends [4].
What are the reported side effects of Akynzeo?
Common side effects associated with Akynzeo treatment include headache, fatigue, constipation, and indigestion. More serious side effects are rare but can include hypersensitivity reactions [2].
How effective is Akynzeo in clinical trials?
Clinical trials have demonstrated Akynzeo's efficacy in preventing both acute and delayed CINV in patients receiving highly and moderately emetogenic chemotherapy. Studies showed statistically significant improvements in the percentage of patients achieving complete response (no vomiting and no rescue medication) compared to placebo or other combination therapies [3].
Who manufactures Akynzeo?
Akynzeo is manufactured by Helsinn Healthcare S.A. [1].